Zhejiang Huahai Pharmaceutical Co., Ltd.

SSE:600521.SS

20.5 (CNY) • At close June 13, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2024202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000
Revenue 9,547.4258,308.728,265.7456,643.5736,485.2135,388.0955,094.5965,002.0034,092.8533,500.3622,584.9882,296.4082,014.3911,827.6141,022.845927.967801.432706.981557.26423.246391.129303.036187.378177.806136.006
Cost of Revenue 3,636.6043,288.3383,110.9362,657.1342,352.2232,126.3832,050.4762,202.6682,052.6651,777.491,430.0741,289.2581,203.2281,103.301593.529541.002430.04377.064287.961189.71193.986141.686.346101.59564.637
Gross Profit 5,910.8215,020.3825,154.8093,986.4394,132.9913,261.7123,044.122,799.3352,040.1881,722.8721,154.9141,007.149811.163724.313429.316386.965371.392329.917269.299233.536197.143161.436101.03276.21171.368
Gross Profit Ratio 0.6190.6040.6240.60.6370.6050.5980.560.4980.4920.4470.4390.4030.3960.420.4170.4630.4670.4830.5520.5040.5330.5390.4290.525
Reseach & Development Expenses 986.685982.994925.529942.264565.697467.358396.759348.269339.396267.089212.752155.75193.31784.63570.0420000000000
General & Administrative Expenses 682.072610.41669.843683.088546.082387.792401.084323.093246.914204.553121.60997.978104.19118.538110.223166.527148.319104.446101.53854.83436.62631.89221.5419.29914.883
Selling & Marketing Expenses 1,572.2261,294.7821,244.2371,179.106996.334960.5451,294.367904.65614.718448.118274.469150.99483.21749.27542.5427.16123.44717.45717.60612.99112.6826.533.9462.9541.417
SG&A 2,254.2981,806.6451,914.081,862.1941,542.4161,348.3371,695.4511,227.742861.632652.671396.078248.972187.407167.813152.763193.688171.766121.902119.14467.82549.30938.42225.48622.25416.3
Other Expenses 1,199.0491,020.757587.67525.255433.09326.402-317.997-11.93362.26436.098-8.68615.247.3671.17731.65926.5942.7794.6827.4558.057.972-4.317-0.622-1.453-0.847
Operating Expenses 4,440.0323,808.0833,427.2783,329.7132,541.2022,142.0982,246.7111,899.7121,511.2771,182.106806.751580.278419.037396.797318.097202.365177.612127.753123.23371.14951.14839.86526.35523.07417.757
Operating Income 1,470.7891,124.541,547.171868.3991,286.555824.375475.239791.179507.898493.1307.361399.848355.969274.1297.182170.42168.481184.787143.263168.992155.914124.59772.7555.34553.15
Operating Income Ratio 0.1540.1350.1870.1310.1980.1530.0930.1580.1240.1410.1190.1740.1770.150.0950.1840.210.2610.2570.3990.3990.4110.3880.3110.391
Total Other Income Expenses Net -7.18-24.218-38.272-81.471-131.418-63.511-198.524-71.12559.06830.69-14.05812.45245.897-0.96530.61925.04-26.112-13.175.487.18516.451-4.622-1.88-1.624-1.019
Income Before Tax 1,463.6081,100.3211,508.9786.9281,215.355760.864157.242779.247567.066523.79312.947412.299401.866273.155127.802195.46167.667188.995148.743176.177163.166119.97572.11253.72152.131
Income Before Tax Ratio 0.1530.1320.1830.1180.1870.1410.0310.1560.1390.150.1210.180.1990.1490.1250.2110.2090.2670.2670.4160.4170.3960.3850.3020.383
Income Tax Expense 356.145283.072332.89306.284220.757154.03922.341155.659110.16787.06956.21648.87763.37259.06634.2731.07317.80956.94838.67547.18744.03940.68221.50710.83717.425
Net Income 1,118.981830.4661,167.759487.535929.815569.595107.515639.247500.831442.472265.501359.168341.123216.90693.587164.978150.066132.026110.014128.913119.11279.28450.59342.6134.349
Net Income Ratio 0.1170.10.1410.0730.1430.1060.0210.1280.1220.1260.1030.1560.1690.1190.0910.1780.1870.1870.1970.3050.3050.2620.270.240.253
EPS 0.770.570.810.340.640.390.0820.460.370.330.20.280.280.180.0750.140.120.110.0890.10.0770.0510.050.0380.031
EPS Diluted 0.770.570.80.340.640.390.0820.460.370.330.20.280.280.180.0750.140.120.110.0890.10.0770.0510.050.0380.031
EBITDA 2,600.1822,155.4042,454.1181,564.8821,855.5971,465.31669.8961,125.576863.374745.766493.904579.862530.442375.555208.702253.229253.582255.418195.327204.419182.029135.47386.61864.44455.382
EBITDA Ratio 0.2720.2590.2970.2360.2860.2720.1310.2250.2110.2130.1910.2530.2630.2050.2040.2730.3160.3610.3510.4830.4650.4470.4620.3620.407